Advil lip a tour of i grow some of the worlds best known drugs could soon be under a new roof well tell you why u. S. Pharma giant pfizer is spinning off its biggest brands. Also on the show like it or leave it europes Top Court Rules against that ubiquitous Facebook Like button on external web pages. And europe single labor market has mostly been a boom for member countries with weak job markets but some you citizens are still off the books the romanian day laborer who moved to italy. This is your Business Report im Stephen Beers in berlin thanks for joining us us drug giant pfizer is spinning off its older branded medications into a merger with generic drug maker milan pfizer would have a Majority Stake in the new business which would both sales of 20000000000. 00 annually and own the rights to some of the most familiar brands of the pharmacy
including advil and cholesterol pill if its worth all of which have lost Patent Protection making them less profitable the spin off would allow
FRANKFURT (Reuters) -Germany's diversified group Merck KGaA flagged that full-year operating earnings would likely be in the lower half of its target range on weak demand for specialty materials that are used to make biotech drugs and semiconductors. The maker of pharmaceuticals, lab gear and specialty chemicals confirmed that 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would come in between 5.8 billion euros ($6.21 billion) and 6.4 billion euros but would be "trending in the lower half of the absolute range". Last month, Merck raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.
FRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic version of Johnson & Johnson's anti-inflammatory drug Stelara under a collaboration deal with Samsung Bioepis. For Sandoz, which is due to become an independent company early next month, the transaction means more investment in the growing market of biosimilars, which are lower-cost copies of complex biotech drugs that have lost patent protection.
On March 15, 2023, the Centers for Medicare & Medicaid Services (CMS) issued an initial guidance memorandum on the Medicare Drug Price Negotiation Program (Negotiation Program) created.